3 results
The primary objective of the Phase 2 portion of the study is to assess if the addition of ABT-751 at the RPTD to standard pemetrexed can prolong PFS compared to pemetrexed alone in subjects with advanced or metastatic NSCLC.
1. To determine the efficacy of CJM112 300 mg in chronic hidradenitis suppurativa (HS) patients, by clinical responder rate at week 16.2. To assess the safety and tolerability of CJM112 in patients with chronic hidradenitis suppurativa (HS)3. To…
To evaluate the safety and efficacy in terms of progression-free survival (PFS) and overall survival (OS) of nintedanib + pemetrexed / cisplatin followed by nintedanib versus placebo + pemetrexed / cisplatin followed by placebo as first line…